- Triple-strength Wegovy 'mega dose' given green light by health officials allowing users to shed 'significantly more weight' with a single injection Daily Mail —
- Novo Nordisk teams up with OpenAI to boost AI-driven drug discovery efforts Seeking Alpha —
- UK approves Novo Nordisk single-dose 7.2mg Wegovy pen for obesity patients Seeking Alpha —
- Novo Nordisk and OpenAI Partner to Speed Drug Discovery Wall Street Journal —
- Wegovy major change from April 14 for certain people using jab to lose weight Mirror —
- Novo Nordisk partners with OpenAI as AI drug discovery hopes mount CNBC —
- Five key weight loss jab side effects reported by 43 percent of patients Mirror —
- Wegovy-maker Novo Nordisk partners with OpenAI to speed drug development - Reuters Reuters —
- Popular weight-loss medications linked to hidden side effects, study finds Fox News —
- Novo Taps OpenAI to Speed Development of New Obesity Drugs Bloomberg —
- Study flags unreported GLP-1 side effects in analysis of social media posts CTV News —
- Thousands are sharing side effects of weight-loss drugs doctors may miss, study suggests CTV News —
- Canadian lab explains puzzling link between semaglutide, better liver health The Globe and Mail —
- Breakingviews - Weight loss drugs face first economic stress test - Reuters Reuters —
- Why weight-loss jabs could improve liver health The Independent —
- US states drop Medicaid coverage of GLP-1 weight-loss drugs as demand rises The Guardian —
Novo Nordisk
Danish pharmaceutical company
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28.1% of its shares and a majority (77.1%) of its voting shares.
Also known as...
Novo Nordisk A/S
Wegovy major changes for patients